CVRFSoCal

We are pleased to report: 🏆 SCCT Best Original Science Award goes to Dr. Joel Lenell, MD, PhD @joellenell at the 20th Annual @Heart_SCCT Scientific Meeting! Supported by @CVRF_SoCal and @CVMGBevHills See the entire competition at youtube.com/watch?v=0lU0AH… #scct2025. Also congratulations to @damini_dey, @SmidtHeart and thanks to @almallahmo for chairing this informative session #SCCT2025 @RonKarlsbergMD

@RonKarlsbergMD @MohammedAlo @drterrysimpson Thank you, @RonKarlsbergMD, for helping patients by broadcasting reliable and helpful data.

Thank you for stepping up and addressing misinformation that directly harms patients and creates confusion. The solution is simple—ask for the data that supports the claims. We all need to push back and move the needle against this constant noise, much of which is driven by self-promotion rather than evidence.

Lol. Statins have been shown to fix all those things. @drterrysimpson

Is your belt sized getting bigger? Obesity isn’t just a look. It’s a warning sign. It’s the gateway to Type 2 diabetes, Hypertension, Nonalcoholic fatty liver disease, Insulin resistance, & even Cancer. We normalize it, ignore it, & then wonder why we’re getting sicker. MAHA

@RonBlankstein @hsbhatia @TCTMD_Yael Congratulations Dr. Bhatia. It was an honor to have you as one of our Research Fellows! @hsbhatia

Useful new data on role of CAC for risk stratifying individuals with elevated Lp(a). 👏 @hsbhatia and colleagues. Thanks @TCTMD_Yael for covering. #ACC26

@ElucidBio The Cardiovascular Research Foundation of Southern California is proud to be a participant in this publication

A new JACC Journals: Case Reports publication highlights an important reality in #cardiovascularcare: high-risk coronary disease can be clinically silent. In this case, advanced coronary CT imaging revealed extensive plaque dominated by lipid-rich necrotic core (#LRNC), a key marker of vulnerable plaque and future coronary events. Read here: sciencedirect.com/science/articl… Key takeaways: • Severe coronary disease may exist without symptoms, underscoring the limits of symptom-based detection • LRNC is a critical marker of plaque vulnerability and future risk • Advanced coronary imaging can reveal hidden disease earlier, enabling more proactive management Studies like this reinforce the importance of detecting true disease earlier—before heart attack or stroke occurs. Congrats to the authors! Drs. @elisarrarasx, Robert Pelberg, Jacob S. Roberts, @JayShah_MD, Jeffrey Xia, Sammy Sayed, Norman Lepor, Jairo Aldana-Bitar, @RonKarlsbergMD, Geoffrey Cho #Cardiology #CCTA #CoronaryPlaque #PreventiveCardiology #CardiovascularImaging #CAD

Join us for the CTA Academy: Coronary CTA Workshop on April 11-12, 2026! Enhance your skills with hands-on learning from experts. Don’t miss out on tackling complex cases! @ToddVillinesMD @AmitPursnaniMD Register: ow.ly/CBuE50YlZaG

@RonKarlsbergMD @Heart_SCCT @DanielKarlsberg @CanonMedicalUS The Cardiovascular Research Foundation is privileged and honored to support the best science at SCCT! @RonBlankstein

Over the past two decades, we have finally reached the threshold where coronary CTA is not only mainstream, but central to mitigating and treating the disease and making a major impact on our number one killer. The SCCT has methodically and persistently moved to place coronary CTA at the center of the evidence base, and we are proud and humbled to be part of that process. #cardiology @DLBHATTMD @DrMarthaGulati @ToddVillinesMD

Submit your research for #SCCT2026! We're accepting standard and educational abstracts. The awards are supported by CVRF of So. Ca. - Ma Family @RonKarlsbergMD @DanielKarlsberg and @CanonMedicalUS. Deadline is TOMORROW March 6. Learn more: scct.org/page/ASMAbsSub…

RT @RonKarlsbergMD: 🚀 New research in Nature Medicine from Stanford shows that large language models (LLMs) can meaningfully boost clinical…

@RonKarlsbergMD This is only the beginning. The way we deliver and provide medicine will need to be completely rebuilt. The integration of AI at the "point of care" is a turning point in healthcare — one of the greatest opportunities to transform medicine for the better.

Looks great @RonKarlsbergMD

Here’s our latest flipbook - flipsnack.com/E5CDBF5569B/ca… via @flipsnack

@RonKarlsbergMD The CVRF foundation is looking forward this this research trial @ACCinTouch @CVMGBevHills @DLBHATTMD

Check linkedin.com/pulse/cutting-…

@RonKarlsbergMD We are pleased to announce our next course starts Saturday March 14, 2026. Email CT@cvmg.com for more information. @UCLAHealth @SmidtHeart @CedarsSinai @Heart_SCCT @UCSFMedicine @UCSF #Cardiology #Radiology #CardiacCT #CardiacImaging #MedicalEducation @jnrmxms

@RonKarlsbergMD @UCLA @CVMGBevHills @SmidtHeart @CedarsSinai @elisarrarasx @JCM_MDPI The Cardiovascular Research Foundation of Southern California is proud to have this amazing team of excellence. We focus on developing new pathways for the evidence base. @ACCinTouch #Cardiology

Our JCM review on AI in Nuclear Cardiac Imaging was selected as an Editor’s Choice (Q1 ’26). 🔗 mdpi.com/2077-0383/14/6… Thanks to our amazing team @UCLA, @CVRF_SoCal @CVMGBevHills @SmidtHeart @CedarsSinai @elisarrarasx @JCM_MDPI #NuclearCardiology #AI #CardiacImaging

Respectfully, the comments are misleading and should be clarified so that we properly present the data and inform the public with accuracy. Large randomized trial meta-analyses show statins do slightly increase new-onset diabetes risk (about 9–12% relative increase), but the absolute risk is small—roughly ~1 extra case per ~250 people treated for ~4 years, and it occurs mostly in people who already have underlying diabetes risk factors (prediabetes, obesity, metabolic syndrome). In other words, statins tend to accelerate diabetes in those predisposed, rather than “cause” it out of nowhere. But still there is a value proposition. Muscle symptoms are reported, but blinded trials show much of the muscle pain signal is also seen on placebo, and serious muscle injury is rare. Meanwhile, statins prevent far more harm—often ~1 major cardiovascular event prevented per ~25–50 treated over ~5 years, depending on baseline risk. So yes, risk is real and already in labeling, but the overall benefit/risk profile remains strongly favorable for most higher-risk patients. Lets keep the discussion fair.

Respectfully, to protect the public space: CAC scoring is a legitimate, guideline-supported risk marker, but it does not directly show “how clogged your arteries are” (it measures calcified plaque burden, not total plaque or degree of blockage). And the claim that one should take Nattokinase needs clarification: Specifically, nattokinase does not have high-quality randomized trial evidence showing it reverses coronary plaque or reduces heart attacks/strokes, so presenting it as a proven plaque-reversal therapy is misleading. The strongest evidence for reducing plaque-related events comes from plaque-directed medical therapy in the evidence base and aggressive risk-factor control, not supplements. Lets keep the public safe and informed.

I learned today that my dear friend and colleague Dr Harvey Hecht passed On January 28. Harvey was a pioneer in CAC and CCTA and was the first president of the society of cardiovascular imaging and a leading preventive cardiologist long before such a profession was fully realized